A batch of a widely prescribed blood pressure medication has been recalled in the United Kingdom following a packaging error that may have led to incorrect dosing. Health authorities have issued guidance to both pharmacies and patients, emphasizing the need for verification rather than alarm.
The recall concerns Ramipril, a medication commonly used to treat high blood pressure, heart failure, and kidney disease. While the issue has prompted swift action from regulators, officials stress that the risk to patients remains low, particularly over short-term use.
Packaging Mix-up Prompts Nationwide Recall
The Medicines and Healthcare products Regulatory Agency (MHRA) announced the recall of one batch of Ramipril 10mg capsules manufactured by Crescent Pharma Limited. According to the MHRA, some cartons labeled as containing 10mg capsules may instead include blister strips of the lower 5mg dose.
The issue was identified after a patient reported finding a mismatch inside a sealed package. According to the MHRA, one complaint revealed that a blister pack of Ramipril 5mg capsules had been placed inside a carton labeled for 10mg capsules. Investigators traced the problem to a manufacturing stage known as secondary packaging, where blister strips are inserted into cartons.
Healthcare professionals have been instructed to immediately stop supplying the affected batch, identified as GR174091, and to return remaining stock to suppliers. Pharmacies are also expected to contact patients who may have received the medication over the past year, with distribution dates ranging from May 2025 to April 2026, according to official guidance.
The recall follows a similar incident reported the previous month involving Ramipril 5mg packs that mistakenly contained a different medication altogether. In both cases, the errors originated at the same manufacturing site, raising concerns about quality control during packaging processes.
Health Risks Considered Low, but Checks Remain Essential
Despite the recall, health officials have emphasized that the immediate risk to patients is limited. According to the MHRA, taking a lower dose of Ramipril than prescribed is unlikely to cause serious harm over a short period. The agency noted that any effects from reduced dosage would likely be gradual rather than sudden or life-threatening.
Dr. Alison Cave, Chief Safety Officer at the MHRA, advised patients to check both the outer carton and the blister strips inside. According to her statement, individuals who find discrepancies should contact their dispensing pharmacy for further guidance. Those whose packaging is consistent do not need to take additional action.
Ramipril works by relaxing blood vessels, making it easier for the heart to pump blood. It is commonly prescribed to prevent complications such as heart attacks and strokes. According to reports, dosing typically starts low and is increased gradually, meaning short-term deviations may not immediately impact treatment outcomes.
Patients experiencing any unusual symptoms are advised to seek medical advice and report concerns through the MHRA’s Yellow Card scheme. Still, the overall message from regulators remains measured: vigilance is necessary, but there is no indication of widespread harm linked to the issue. The recall highlights the importance of routine checks in medication use, particularly when manufacturing errors, however rare, can affect labeling and dosage accuracy.
